ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based ...
Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses. The restricted mean survival time (RMST) analysis technique was introduced in health care ...
ImmunityBio Inc. IBRX shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...
In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...
The rapid evolution of mass spectrometry (MS) has transformed biological research, yet the reliability of these insights depends entirely on the rigor of the applied proteomics statistics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results